Who are sublingual immunotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Staloral 300, Novel dose adjustment of Alutard SQ, Cupressus arizonica, HDM 12 SQ-HDM, ragweed pollen, wasp venom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sublingual-immunotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

sublingual immunotherapy — Competitive Intelligence Brief

sublingual immunotherapy (sublingual immunotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

marketed Allergen immunotherapy Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

sublingual immunotherapy (sublingual immunotherapy) — University of Genova. Sublingual immunotherapy delivers allergen extracts under the tongue to induce immune tolerance and reduce allergic responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
sublingual immunotherapy TARGET	sublingual immunotherapy	University of Genova	marketed	Allergen immunotherapy
Staloral 300	Staloral 300	Medical University of Lodz	marketed	Allergen immunotherapy (sublingual tablet)	Grass pollen allergens (Phleum pratense and related species)
Novel dose adjustment of Alutard SQ	Novel dose adjustment of Alutard SQ	Beijing Tongren Hospital	marketed	Allergen immunotherapy
Cupressus arizonica	Cupressus arizonica	Laboratorios Leti, S.L.	marketed	Allergen immunotherapy
HDM 12 SQ-HDM	HDM 12 SQ-HDM	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)
ragweed pollen	ragweed pollen	The University of Texas Medical Branch, Galveston	marketed	Allergen immunotherapy
wasp venom	wasp venom	Allergopharma GmbH & Co. KG	marketed	Allergen immunotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sublingual immunotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/sublingual-immunotherapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab